Recombinant Erythropoietin for Anaemia of Prematurity—When Should Treatment Start?

Publisher： John Wiley & Sons Inc

E-ISSN： 2055-2335|37|3|217-219

ISSN： 1445-937x

Source： JOURNAL OF PHARMACY PRACTICE AND RESEARCH, Vol.37, Iss.3, 2007-09, pp. : 217-219

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Human Recombinant Erythropoietin in the Prevention and Treatment of Anemia of Prematurity

By Ohls R.K.  

Pediatric Drugs, Vol. 4, Iss. 2, 2002-01 ,pp. : 111-121

Adis International

Access to resources Recommend Favorite

Recombinant erythropoietin favoured in chemo-related anaemia

By  

Inpharma, Vol. 1, Iss. 1587, 2007-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Recombinant erythropoietin favoured in chemo-related anaemia

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 527, 2007-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Recombinant Human Erythropoietin for the Treatment of Renal Anaemia in Children: No Justification for Bodyweight-Adjusted Dosage

By Port R.E.  

Clinical Pharmacokinetics, Vol. 43, Iss. 1, 2004-01 ,pp. : 57-70

Adis International

Access to resources Recommend Favorite

Cost Effectiveness, Quality-Adjusted Life-Years and Supportive Care: Recombinant Human Erythropoietin as a Treatment of Cancer-Associated Anaemia

By Cremieux P-Y.  

PharmacoEconomics, Vol. 16, Iss. 5, 1999-11 ,pp. : 459-472

Adis International

Access to resources Recommend Favorite